IBT vs. JUSC, BGUK, CGL, MNL, ASLI, MTE, RECI, ADIG, CCJI, and BGHS
Should you be buying International Biotechnology stock or one of its competitors? The main competitors of International Biotechnology include JPMorgan US Smaller Companies (JUSC), Baillie Gifford UK Growth Trust (BGUK), Castelnau Group (CGL), Manchester & London Investment Trust (MNL), abrdn European Logistics Income (ASLI), Montanaro European Smaller (MTE), Real Estate Credit Investments (RECI), abrdn Diversified Income & Growth (ADIG), CC Japan Income & Growth Trust (CCJI), and Boussard & Gavaudan GBP (BGHS). These companies are all part of the "asset management" industry.
International Biotechnology (LON:IBT) and JPMorgan US Smaller Companies Investment Trust (LON:JUSC) are both small-cap financial services companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, dividends, analyst recommendations, institutional ownership, community ranking, valuation and profitability.
52.1% of International Biotechnology shares are held by institutional investors. Comparatively, 28.8% of JPMorgan US Smaller Companies Investment Trust shares are held by institutional investors. 4.7% of International Biotechnology shares are held by insiders. Comparatively, 20.5% of JPMorgan US Smaller Companies Investment Trust shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
International Biotechnology has a net margin of 84.61% compared to JPMorgan US Smaller Companies Investment Trust's net margin of 75.38%. International Biotechnology's return on equity of 15.33% beat JPMorgan US Smaller Companies Investment Trust's return on equity.
In the previous week, JPMorgan US Smaller Companies Investment Trust had 3 more articles in the media than International Biotechnology. MarketBeat recorded 3 mentions for JPMorgan US Smaller Companies Investment Trust and 0 mentions for International Biotechnology. JPMorgan US Smaller Companies Investment Trust's average media sentiment score of 0.62 beat International Biotechnology's score of 0.00 indicating that JPMorgan US Smaller Companies Investment Trust is being referred to more favorably in the news media.
International Biotechnology has higher revenue and earnings than JPMorgan US Smaller Companies Investment Trust. International Biotechnology is trading at a lower price-to-earnings ratio than JPMorgan US Smaller Companies Investment Trust, indicating that it is currently the more affordable of the two stocks.
International Biotechnology pays an annual dividend of GBX 28 per share and has a dividend yield of 4.4%. JPMorgan US Smaller Companies Investment Trust pays an annual dividend of GBX 3 per share and has a dividend yield of 0.8%. International Biotechnology pays out 2,666.7% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. JPMorgan US Smaller Companies Investment Trust pays out 1,666.7% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.
International Biotechnology has a beta of 0.18, suggesting that its share price is 82% less volatile than the S&P 500. Comparatively, JPMorgan US Smaller Companies Investment Trust has a beta of 1.14, suggesting that its share price is 14% more volatile than the S&P 500.
International Biotechnology received 41 more outperform votes than JPMorgan US Smaller Companies Investment Trust when rated by MarketBeat users. Likewise, 77.71% of users gave International Biotechnology an outperform vote while only 64.63% of users gave JPMorgan US Smaller Companies Investment Trust an outperform vote.
Summary
International Biotechnology beats JPMorgan US Smaller Companies Investment Trust on 10 of the 17 factors compared between the two stocks.
Get International Biotechnology News Delivered to You Automatically
Sign up to receive the latest news and ratings for IBT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IBT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
International Biotechnology Competitors List
Related Companies and Tools
